Protalix BioTherapeutics/PLX

$1.48

2.07%
-
1D1W1MYTD1YMAX

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.

Ticker

PLX

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Dror Bashan

Employees

193

Headquarters

Hackensack, United States

PLX Metrics

BasicAdvanced
$105.78M
Market cap
18.30
P/E ratio
$0.08
EPS
0.88
Beta
-
Dividend rate

What the Analysts think about PLX

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 2 analysts.
778.38% upside
High $16.00
Low $10.00
$1.48
Current price
$13.00
Average price target

PLX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-17.47% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$10.3M
-70.57%
Net income
$-1.8M
-109.33%
Profit margin
-17.47%
-131.68%

PLX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 42.86%
QuarterlyAnnual
Q3 22
Q4 22
Q2 23
Q3 23
Q4 23
Actual
-$0.07
-$0.07
$0.21
-$0.04
-
Expected
-$0.15
-$0.15
-$0.04
-$0.07
-$0.03
Surprise
-53.33%
-53.33%
-625%
-42.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Protalix BioTherapeutics stock

Buy or sell Protalix BioTherapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing